Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …

Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …

Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown
to be well tolerated with a good safety profile in individuals aged 18 years and older in …

Predictive models of immune protection from COVID-19 are urgently needed to identify
correlates of protection to assist in the future deployment of vaccines. To address this, we …

Background A vaccine against SARS-CoV-2 for children and adolescents will play an
important role in curbing the COVID-19 pandemic. Here we aimed to assess the safety …

The development of effective vaccines to combat infectious diseases is a complex multi-year
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …

COVID-19 vaccines were developed with an unprecedented pace since the beginning of the
pandemic. Several of them have reached market authorization and mass production …

Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by
the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of …

Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

To the Editor—The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants in places where the virus is uncontained poses a global threat from the …